Novo Nordisk is lowering the advertised U.S. prices for Ozempic (a diabetes drug) and Wegovy (a weight-loss drug) by as much as 50%. This is the company's move to make these expensive medications more affordable for patients and insurers.

• •Novo Nordisk to cut US list prices for Ozempic and Wegovy by up to 50%
• •Move targets affordability for patients and insurers

Boehringer Ingelheim and Zealand Pharma's obesity drug showed results in a Phase 3 trial (a late-stage test) that resembled Novo Nordisk's Wegovy (a popular weight-loss medicine). The comparison suggests the drug may be competitive in the weight-loss market.

• •Boehringer/Zealand obesity drug posted Phase 3 results compared to Novo's Wegovy
• •Trial profile described as 'more akin' to Wegovy

Novo Nordisk's CEO discussed the U.S. approval path for an oral version of Wegovy (a weight-loss drug) while also addressing concerns that Middle East tensions could disrupt the company's supply chains. The comments highlight both regulatory hopes for a pill form and real-world risks to drug manufacturing and delivery.

• •Novo Nordisk CEO commented on U.S. approval path for an oral version of Wegovy
• •CEO addressed risk that Middle East tensions could disrupt supply chains

• •Morningstar rates Novo Nordisk stock as heavily overvalued at an 85% premium
• •Wegovy competition is intensifying per Morningstar's assessment